Scholarlink

<p>Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection can reduce CRC mortality by more than 90%. Circulating small extracellular vesicles (sEVs) are emerging as promising biomarkers for CRC, but their role in detecting precancerous lesions remains unclear. Herein, parallel proteomic and phosphoproteomic analyses of plasma-derived sEVs were performed in healthy subjects with negative colonoscopy, patients with high-risk adenoma (HRA) and patients with CRC. A total of 139 phosphorylation sites on 52 proteins were identified, among which 16 phosphorylation sites on 12 sEV proteins showed significant changes (≥&#xa0;2-fold) with 90% confidence in site localization. Web-based validation demonstrated that the phosphorylation level of sEV-derived filamin-A at serine 1459 (pFLNA<sup>Ser1459</sup>) correlated with the Clinical Proteomic Tumor Analysis Consortium colon cancer dataset. Immunoblot analysis confirmed that sEV-derived pFLNA<sup>Ser1459</sup> was significantly reduced in CRC patients compared with healthy subjects, whereas the highest levels were observed in HRA patients. Notably, sEV-derived pFLNA<sup>Ser1459</sup>, alone or in combination with FLNA, CD9, and TSG101, showed superior diagnostic performance in distinguishing HRA patients from CRC patients and healthy subjects. These findings suggest that plasma sEV-derived pFLNA<sup>Ser1459</sup> is a promising biomarker for colorectal neoplasm detection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phosphorylated filamin-A at serine 1459 from plasma-derived small extracellular vesicles as a promising biomarker for high-risk adenoma and colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Chris Verathamjamras,
  • Juthamard Chantaraamporn,
  • Juthaporn Sangwallek,
  • Ladawan Khowawisetsut,
  • Sasivimon Pramual,
  • Phichamon Phetchahwang,
  • Khajeelak Chiablaem,
  • Daranee Chokchaichamnankit,
  • Kanitta Srinoun,
  • Natta Tansila,
  • Worrawit Wanichsuwan,
  • Chantragan Srisomsap,
  • Voraratt Champattanachai,
  • Aekkaraj Nualla-ong,
  • Kovit Pattanapanyasat,
  • Jisnuson Svasti,
  • Supinya Thanapongpichat,
  • Churat Weeraphan,
  • Hansuk Buncherd

摘要

Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection can reduce CRC mortality by more than 90%. Circulating small extracellular vesicles (sEVs) are emerging as promising biomarkers for CRC, but their role in detecting precancerous lesions remains unclear. Herein, parallel proteomic and phosphoproteomic analyses of plasma-derived sEVs were performed in healthy subjects with negative colonoscopy, patients with high-risk adenoma (HRA) and patients with CRC. A total of 139 phosphorylation sites on 52 proteins were identified, among which 16 phosphorylation sites on 12 sEV proteins showed significant changes (≥ 2-fold) with 90% confidence in site localization. Web-based validation demonstrated that the phosphorylation level of sEV-derived filamin-A at serine 1459 (pFLNASer1459) correlated with the Clinical Proteomic Tumor Analysis Consortium colon cancer dataset. Immunoblot analysis confirmed that sEV-derived pFLNASer1459 was significantly reduced in CRC patients compared with healthy subjects, whereas the highest levels were observed in HRA patients. Notably, sEV-derived pFLNASer1459, alone or in combination with FLNA, CD9, and TSG101, showed superior diagnostic performance in distinguishing HRA patients from CRC patients and healthy subjects. These findings suggest that plasma sEV-derived pFLNASer1459 is a promising biomarker for colorectal neoplasm detection.